EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma

Abstract excerpt

Abstract Purpose: Exploration of novel strategies to extend the benefit of PARP inhibitors beyond BRCA-mutant cancers is of great interest in personalized medicine. Here, we identified EGFR amplification as a potential biomarker to predict sensitivity to PARP inhibition, providing selection for the glioblastoma (GBM) patient population who will benefit from PARP inhibition therapy. Experimental Design: Selective...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Repair Mechanisms
• Share to Glioma Diagnosis and Treatment
• Share to PARP inhibition in cancer therapy